Lilly is leading on

Transparency

How Lilly conducts its business is equally as important as the work it does on a daily basis. Lilly's core values - integrity, excellence and respect for people - are reflected in business practices that include strong governance principles, the ethical development of medicines, transparency and ethical product promotion. 

Clinical Trials and Animal Research

Lilly supports responsible sharing of clinical study data and, whether the results were favourable or unfavourable, posts the results of all Lilly-sponsored Phase II, Phase III and Phase IV clinical trials of Lilly marketed products conducted anywhere in the world that were initiated on or after October 15, 2002 on www.clinicaltrials.gov. Lilly upholds the highest standards of animal care in our research in line with international laws and guidance, and has a stringent set of company principles that ensure all staff involved in working with animals are appropriately trained and qualified. Lilly was one of the first organisations to sign the Concordat on Openness in Animal Research in 2014; this declaration includes four commitments to increasing transparency and set out how organisations will be more open about the ways in which animals are used in scientific, medical and veterinary research in the UK. 

Please use the links below to find more information:

Payments and Joint Working

Across Europe the pharmaceutical industry has committed to disclose the payments that it makes to healthcare professionals (HCPs) and organisations (HCOs) through adoption of the European Pharmaceutical Industry’s HCP/HCO Disclosure Code. From 2016, payments to UK HCPs and HCOs are disclosed via a centralised database; www.disclosureuk.org.uk.  In addition, we publish details of joint working projects that we undertake with the NHS. Please use the links below to find more information:

ANTI-COUNTERFEITING
Learn more about what Lilly is doing to combat counterfeiting